TN2009000318A1 - Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof - Google Patents

Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof

Info

Publication number: TN2009000318A1
Authority: TN; Tunisia
Prior art keywords: dihydro; aryl; naphthyridinamides; substituted; diseases
Prior art date: 2007-02-27

Application number

TNP2009000318A

Other languages

English (en)

Inventor

Lars Barfacker

Peter Kolkhof

Karl-Heinz Schlemmer

Rolf Grosser

Adam Nitsche

Martina Klein

Klaus Munter

Barbara Albrecht-Kupper

Elke Hartmann

Original Assignee

Bayer Schering Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-27

Filing date

2009-07-30

Publication date

2010-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39512753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000318(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-07-30 Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag

2010-12-31 Publication of TN2009000318A1 publication Critical patent/TN2009000318A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pigments, Carbon Blacks, Or Wood Stains (AREA)

TNP2009000318A 2007-02-27 2009-07-30 Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof TN2009000318A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102007009494A DE102007009494A1 (de)	2007-02-27	2007-02-27	Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
PCT/EP2008/001257 WO2008104306A2 (fr)	2007-02-27	2008-02-19	Amides de 4-aryl-1,4-dihydro-1,6-naphthyridine substitués et utilisation de ceux-ci

Publications (1)

Publication Number	Publication Date
TN2009000318A1 true TN2009000318A1 (en)	2010-12-31

Family

ID=39512753

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000318A TN2009000318A1 (en)	2007-02-27	2009-07-30	Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof

Country Status (46)

Country	Link
US (2)	US8436180B2 (fr)
EP (1)	EP2132206B1 (fr)
JP (2)	JP5367586B2 (fr)
KR (1)	KR101614164B1 (fr)
CN (1)	CN101641352B (fr)
AR (1)	AR065463A1 (fr)
AU (1)	AU2008221071B2 (fr)
BR (2)	BRPI0808098B8 (fr)
CA (1)	CA2679232C (fr)
CL (1)	CL2008000502A1 (fr)
CO (1)	CO6220951A2 (fr)
CR (1)	CR10976A (fr)
CU (1)	CU23874B1 (fr)
CY (2)	CY1116455T1 (fr)
DE (1)	DE102007009494A1 (fr)
DK (1)	DK2132206T3 (fr)
DO (1)	DOP2009000205A (fr)
EC (1)	ECSP099581A (fr)
ES (1)	ES2540803T3 (fr)
FR (1)	FR22C1017I2 (fr)
GT (1)	GT200900230A (fr)
HN (1)	HN2009001597A (fr)
HR (1)	HRP20150702T1 (fr)
HU (2)	HUE026441T2 (fr)
IL (1)	IL200060A (fr)
JO (1)	JO3018B1 (fr)
LT (1)	LTC2132206I2 (fr)
LU (1)	LUC00260I2 (fr)
MA (1)	MA31245B1 (fr)
MX (1)	MX2009008701A (fr)
MY (2)	MY176873A (fr)
NL (1)	NL301192I2 (fr)
NO (1)	NO2022013I1 (fr)
NZ (1)	NZ579230A (fr)
PA (1)	PA8770101A1 (fr)
PE (1)	PE20090724A1 (fr)
PL (1)	PL2132206T3 (fr)
PT (1)	PT2132206E (fr)
SA (1)	SA08290071B1 (fr)
SI (1)	SI2132206T1 (fr)
TN (1)	TN2009000318A1 (fr)
TW (2)	TWI415608B (fr)
UA (1)	UA102065C2 (fr)
UY (3)	UY30931A1 (fr)
WO (1)	WO2008104306A2 (fr)
ZA (1)	ZA200905730B (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011107494A1 (fr)	2010-03-03	2011-09-09	Sanofi	Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
EP2575821B1 (fr)	2010-05-26	2015-08-12	Satiogen Pharmaceuticals, Inc.	Inhibiteurs de recyclage d'acide biliaire et satiogènes pour traitement du diabète, de l'obésité et d'états inflammatoires gastro-intestinaux
EP2582709B1 (fr)	2010-06-18	2018-01-24	Sanofi	Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2567959B1 (fr)	2011-09-12	2014-04-16	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013037390A1 (fr)	2011-09-12	2013-03-21	Sanofi	Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr)	2011-09-27	2015-10-21	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
CA2852957C (fr)	2011-10-28	2020-08-04	Lumena Pharmaceuticals, Inc.	Inhibiteurs du recyclage de l'acide biliaire pour traitement de l'hypercholemie et de la maladie cholestatique hepatique
JP6217938B2 (ja)	2011-10-28	2017-10-25	ルメナファーマシューティカルズエルエルシー	小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
WO2014095645A1 (fr)	2012-12-17	2014-06-26	General Electric Company	Détection par résonance magnétique in vitro d'une substance cible
EP2968262A1 (fr)	2013-03-15	2016-01-20	Lumena Pharmaceuticals, Inc.	Inhibiteurs de recyclage d'acide biliaire pour le traitement de l' sophage de barrett et du reflux gastro sophagien pathologique
WO2014144650A2 (fr)	2013-03-15	2014-09-18	Lumena Pharmaceuticals, Inc.	Inhibiteurs du recyclage de l'acide biliaire pour le traitement de l'angiocholite sclérosante primaire et de la maladie inflammatoire de l'intestin
CN103193704B (zh) *	2013-04-12	2016-03-09	四川铂瑞生物医药有限公司	2-羟基-4-氨基-5-甲基吡啶杂环化合物
EA029518B1 (ru)	2014-06-30	2018-04-30	Астразенека Аб	Бензоксазиноновые амиды в качестве модуляторов минералокортикоидного рецептора
EP3174875B1 (fr)	2014-08-01	2020-08-19	Bayer Pharma Aktiengesellschaft	Procédé pour fabriquer du (4s)-4-(4-cyano-2-méthoxyphényl)-5-éthoxy-2,8-diméthyl-1,4-dihydro-1,6-naphthyridin-3-carboxamide et le purifier en vue de l'utiliser en tant que principe actif pharmaceutique
WO2017006254A1 (fr)	2015-07-08	2017-01-12	Novartis Ag	Combinaison de médicaments comprenant un antagoniste du récepteur de l'angiotensine ii, un inhibiteur d'endopeptidase neutre et un antagoniste du récepteur de minéralocorticoïdes
CA2995905A1 (fr) *	2015-08-21	2017-03-02	Bayer Pharma Aktiengesellschaft	Procede de preparation de (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphtyridine-3-carboxamide et de purification de ce dernier afin de l'utiliser en tant que principe actif pharmaceutique
RU2018109763A (ru) *	2015-08-21	2019-09-23	Байер Фарма Акциенгезельшафт	Способ получения метаболитов (4s)-и (4r)-4-(4-циано-2-метоксифенил)-5-этокси-2,8-диметил-1,4-дигидро-1,6-нафтиридин-3-карбоксамида и их применение
SI3337801T1 (sl) *	2015-08-21	2019-08-30	Bayer Pharma Aktiengesellschaft	Postopek priprave (4S)-4-(4-ciano-2-metoksifenil)-5-etoksi-2,8-dimetil- 1,4-dihidro-1-6-nafthiridin-3-karboksamida in pridobivanje (4S)-4-(4-ciano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1-6- nafthiridin-3-karboksamida po elektrokemičnih postopkih
WO2017064121A1 (fr)	2015-10-13	2017-04-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Méthodes et compositions pharmaceutiques pour le traitement de la néovascularisation choroïdienne
MX2018006474A (es)	2015-12-02	2018-08-01	Syngenta Participations Ag	Derivados de oxadiazol microbicidas.
WO2018019843A1 (fr)	2016-07-26	2018-02-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antagonistes du récepteur des minéralocorticoïdes pour le traitement de l'arthrose
EP3525779B1 (fr) *	2016-10-11	2024-06-05	Bayer Pharma Aktiengesellschaft	Combinaison contenant le stimulateur sgc vericugat et l'antagoniste des récepteurs minéralcorticoïdes finerenone
EP3525778A1 (fr)	2016-10-11	2019-08-21	Bayer Pharma Aktiengesellschaft	Combinaison contenant des activateurs gcs et des antagonistes du récepteur des minéralocorticoïdes
WO2018153898A1 (fr) *	2017-02-22	2018-08-30	Bayer Pharma Aktiengesellschaft	Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec des antagonistes du récepteur des minéralocorticoïdes
WO2018219825A1 (fr)	2017-06-02	2018-12-06	Syngenta Participations Ag	Dérivés d'oxadiazole microbiocides
DE102017008472A1 (de)	2017-09-08	2018-05-03	Bayer Pharma Aktiengesellschaft	Kombination enthaltend PDE5 Inhibitoren und Mineralocorticoid-Rezeptor-Antagonisten
CN109721536B (zh) *	2017-10-27	2020-11-24	广东东阳光药业有限公司	苯基取代的稠合三环类化合物及其用途
EP3560922A1 (fr)	2018-04-24	2019-10-30	Bayer Aktiengesellschaft	Procédé de preparation de (4s) - 4- (4-cyano-2-methoxyphenyl) -5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide par résolution racémique par esters d'acide tartrique
WO2019223629A1 (fr) *	2018-05-22	2019-11-28	广东东阳光药业有限公司	Composé de dihydronaphtyridine substitué par phényle et son utilisation
CN110917195A (zh) *	2018-08-20	2020-03-27	山西惠尔健生物科技有限公司	肌松剂阿库氯铵（Alcuronium chloride）可作为抗心律失常药物
BR112021015815A2 (pt)	2019-02-12	2022-01-18	Mirum Pharmaceuticals Inc	Métodos para tratar colestase
AU2020230965A1 (en)	2019-03-05	2021-09-23	Bayer Aktiengesellschaft	Synthesis of 4-amino-5-methyl-1H-pyridin-2(1H)-on (intermediate compound for the synthesis of the MR antagonist finerenone) from 2-chloro-5-methyl-4-nitro-pyridine-1-oxide using the intermediate compound 2-chloro-5-methyl-4-pyridinamine
AU2020233169A1 (en)	2019-03-05	2021-09-23	Bayer Aktiengesellschaft	Process for preparing 4-amino-5-methylpyridone
WO2021074072A1 (fr) *	2019-10-17	2021-04-22	Bayer Aktiengesellschaft	Procédé de préparation de (2-cyanoéthyl (4s)-4-(4-cyano-2-méthoxy-phényl)-5-hydroxy-2,8-diméthyl-1,4-dihydro-1,6-naphtyridin-3-carboxylate par séparation racémique au moyen d'esters d'acide tartrique diastéréoisomères
MX2022004466A (es)	2019-10-17	2022-05-03	Bayer Ag	Procedimiento fotoquimico para la preparacion de (4r,4s)-4-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro -1,6-naftiridin-3-carboxamida.
IL292194A (en) *	2019-10-17	2022-06-01	Bayer Ag	Process for the production of acyloxymethyl esters of (4s)-(4-cyano-2-methoxyphenyl)-5-ethoxy-8,2-dimethyl-4,1-dihydro-6,1-naphthyridine-3-carboxylic acid
AU2020367978A1 (en) *	2019-10-17	2022-05-12	Bayer Aktiengesellschaft	Process for the preparation of 2-cyanoethyl (4S)-4-(4-cyano-2-methoxy-phenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylate by resolution of racemates by means of diastereomeric tartaric acid esters
US20230151425A1 (en)	2020-03-11	2023-05-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
CA3180674A1 (fr)	2020-04-22	2021-10-28	Bayer Aktiengesellschaft	Combinaison de finerenone et d'un inhibiteur de sglt2 pour le traitement et/ou la prevention de maladies cardiovasculaires et/ou renales
EP3900722A1 (fr)	2020-04-22	2021-10-27	Bayer AG	Association de finerenone et de pecavaptan pour le traitement et / ou la prevention des maladies cardiovasculaires et / ou renales
WO2021213493A1 (fr) *	2020-04-24	2021-10-28	东莞市东阳光新药研发有限公司	Forme cristalline d'un composé de dihydronaphtyridine et son utilisation
CN113549066B (zh) *	2020-04-24	2023-07-21	年衍药业(珠海)有限公司	二氢萘啶类化合物的晶型及其用途
WO2021254896A1 (fr)	2020-06-16	2021-12-23	Bayer Aktiengesellschaft	Procédé de préparation de (4s)-4-(4-cyano-2-méthoxyphényl)-5-éthoxy-2,8-diméthyl-1,4-dihydro-1,6-naphtyridine-3-carboxamide activé par une réduction catalytique asymétrique par esters de hantzsch
WO2022214206A1 (fr)	2021-04-08	2022-10-13	Bayer Aktiengesellschaft	Combinaison de finérénone et de pecavaptan pour le traitement et/ou la prévention de maladies cardiovasculaires et/ou rénales
EP4373476A1 (fr) *	2021-07-21	2024-05-29	Cyta Therapeutics, Inc.	Administration de particules d'agonistes et d'antagonistes de récepteur d'hormone thyroïdienne
WO2023031277A1 (fr)	2021-08-31	2023-03-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Méthodes de traitement de la rosacée oculaire
MX2024003130A (es)	2021-09-18	2024-04-10	Tuojie Biotech Shanghai Co Ltd	Amida 1,4-dihidro-1,6-naftiridina sustituida y uso de la misma.
CN114149427A (zh) *	2021-12-18	2022-03-08	上海鼎雅药物化学科技有限公司	非奈利酮及其中间体的合成方法
US20250270184A1 (en)	2022-04-18	2025-08-28	Teva Pharmaceuticals International Gmbh	Processes for the preparation of finerenone
EP4286368A1 (fr)	2022-05-31	2023-12-06	Bayer Aktiengesellschaft	Procédé de production de 4-formyl-3-méthoxybenzonitrile
WO2024022481A1 (fr) *	2022-07-29	2024-02-01	苏中药业集团股份有限公司	Composés de dihydronaphtyridine à substitution phényle, leur préparation et leur utilisation
CN120607528A (zh) *	2022-08-30	2025-09-09	杭州科巢生物科技有限公司	非奈利酮的制备方法及其关键手性中间体
KR20250099382A (ko)	2022-11-04	2025-07-01	난징 브이케어 파마테크 씨오., 엘티디.	부분입체 이성질체 타르타르산 에스테르를 이용하여 라세미체를 분리하여 피네레논을 제조하는 방법
KR20250105629A (ko)	2022-11-23	2025-07-08	바이엘 악티엔게젤샤프트	유형 i 당뇨병에서의 만성 신장 질환의 치료
KR20250121106A (ko)	2022-12-16	2025-08-11	바이엘 악티엔게젤샤프트	4-(4-시아노-2-메톡시페닐)-5-에톡시-2,8-디메틸-1,4-디히드로-1,6-나프티리딘-3-카르복스아미드의제조를 위한 순차적 원-포트 합성
CN116082334B (zh) *	2023-01-12	2025-12-09	上海新礼泰药业有限公司	非奈利酮及其中间体的制备方法
CN116041347B (zh) *	2023-01-12	2025-12-09	上海新礼泰药业有限公司	非奈利酮中间体的制备方法
TW202438065A (zh) *	2023-03-17	2024-10-01	大陸商江蘇恒瑞醫藥股份有限公司	1,4-二氫-1,6-萘啶醯胺化合物的可藥用鹽、晶型及其製備方法
WO2024246787A1 (fr)	2023-05-31	2024-12-05	제이더블유중외제약 주식회사	Procédé de préparation de finerénone, composé intermédiaire de finerénone et procédé de préparation du composé intermédiaire
CN116715664B (zh) *	2023-06-12	2025-01-17	常州制药厂有限公司	一种非奈利酮关键中间体的制备方法
CN119306715A (zh) *	2023-07-11	2025-01-14	苏中药业集团股份有限公司	苯基取代的二氢萘啶类化合物的晶体及其用途
CN120081840A (zh) *	2023-12-01	2025-06-03	山东诚创蓝海医药科技有限公司	一种非奈利酮-马来酸共晶及其制备方法
US20250313559A1 (en)	2024-01-05	2025-10-09	Bayer Aktiengesellschaft	Method of preventing or treating heart failure in a patient using (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
WO2025224069A1 (fr)	2024-04-23	2025-10-30	Bayer Aktiengesellschaft	Co-cristaux de finérénone, de pecavaptan et d'inhibiteurs de sglt2
WO2025247801A1 (fr)	2024-05-30	2025-12-04	Bayer Aktiengesellschaft	Détermination d'un dosage d'un antagoniste du récepteur minéralocorticoïde non stéroïdien

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3502831A1 (de)	1985-01-29	1986-07-31	Gödecke AG, 1000 Berlin	1,6-naphthyridinon-derivate, verfahren zu deren herstellung und deren verwendung
US4698341A (en)	1983-07-30	1987-10-06	Godecke Aktiengesellschaft	Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis
DE3327650A1 (de)	1983-07-30	1985-02-14	Gödecke AG, 1000 Berlin	1,6-naphthyridinon-derivate, verfahren zu deren herstellung und deren verwendung bei der bekaempfung von gefaesserkrankungen
IL75987A (en)	1984-08-25	1991-07-18	Goedecke Ag	Tri-and tetrasubstituted-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
DE3431303A1 (de)	1984-08-25	1986-02-27	Goedecke Ag	1,6-naphthyridin-derivate, verfahren zu deren herstellung und deren verwendung
US4760081A (en)	1984-08-25	1988-07-26	Goedecke Aktiengesellschaft	1,6-naphthyridine derivatives useful for treating diseases of the blood vessels
DE19834047A1 (de)	1998-07-29	2000-02-03	Bayer Ag	Substituierte Pyrazolderivate
DE19834044A1 (de)	1998-07-29	2000-02-03	Bayer Ag	Neue substituierte Pyrazolderivate
DE19943636A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de)	1999-09-13	2001-04-12	Bayer Ag	Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
WO2002010164A2 (fr)	2000-08-02	2002-02-07	Abbott Laboratories	Compositions utiles pour ouvrir des canaux potassium au dihydronaphthyridine
AR031176A1 (es)	2000-11-22	2003-09-10	Bayer Ag	Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de)	2001-03-07	2002-09-12	Bayer Ag	Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de)	2001-03-07	2002-09-12	Bayer Ag	Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10220570A1 (de)	2002-05-08	2003-11-20	Bayer Ag	Carbamat-substituierte Pyrazolopyridine
US7135575B2 (en) *	2003-03-03	2006-11-14	Array Biopharma, Inc.	P38 inhibitors and methods of use thereof
US7563748B2 (en)	2003-06-23	2009-07-21	Cognis Ip Management Gmbh	Alcohol alkoxylate carriers for pesticide active ingredients
DE102004012365A1 (de)	2004-03-13	2005-09-29	Bayer Healthcare Ag	Substituierte Dihydropyridine
JP2007230869A (ja)	2004-04-05	2007-09-13	Takeda Chem Ind Ltd	アルドステロン受容体拮抗剤
RU2346996C2 (ru)	2004-06-29	2009-02-20	ЮРОПИЭН НИКЕЛЬ ПиЭлСи	Усовершенствованное выщелачивание основных металлов
RU2007126551A (ru)	2004-12-13	2009-01-20	Айрм Ллк (Bm)	Соединения и композиции, как модуляторы стероидных рецепторов и активности кальциевых каналов
AU2006264212B2 (en)	2005-06-29	2010-10-28	Compumedics Limited	Sensor assembly with conductive bridge
DE102005034264A1 (de)	2005-07-22	2007-02-01	Bayer Healthcare Ag	4-Chromenonyl-1,4-dihydropyridincarbonitrile und ihre Verwendung
DE102006026585A1 (de) *	2006-06-07	2007-12-13	Bayer Healthcare Aktiengesellschaft	Substituierte 4-Aryl-1,4-dihydro-1,6-naphthyridine und ihre Verwendung
DE102006026583A1 (de) *	2006-06-07	2007-12-13	Bayer Healthcare Aktiengesellschaft	Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung

2007
- 2007-02-27 DE DE102007009494A patent/DE102007009494A1/de not_active Withdrawn
2008
- 2008-02-17 SA SA8290071A patent/SA08290071B1/ar unknown
- 2008-02-18 PA PA20088770101A patent/PA8770101A1/es unknown
- 2008-02-19 US US12/526,951 patent/US8436180B2/en active Active
- 2008-02-19 BR BRPI0808098A patent/BRPI0808098B8/pt active IP Right Grant
- 2008-02-19 HR HRP20150702TT patent/HRP20150702T1/hr unknown
- 2008-02-19 AU AU2008221071A patent/AU2008221071B2/en active Active
- 2008-02-19 WO PCT/EP2008/001257 patent/WO2008104306A2/fr not_active Ceased
- 2008-02-19 PE PE2008000351A patent/PE20090724A1/es active IP Right Grant
- 2008-02-19 NZ NZ579230A patent/NZ579230A/en unknown
- 2008-02-19 BR BR122020008544A patent/BR122020008544B8/pt active IP Right Grant
- 2008-02-19 JP JP2009550238A patent/JP5367586B2/ja active Active
- 2008-02-19 MY MYPI2013000708A patent/MY176873A/en unknown
- 2008-02-19 EP EP08715849.9A patent/EP2132206B1/fr active Active
- 2008-02-19 DK DK08715849.9T patent/DK2132206T3/en active
- 2008-02-19 UA UAA200909818A patent/UA102065C2/ru unknown
- 2008-02-19 KR KR1020097017818A patent/KR101614164B1/ko active Active
- 2008-02-19 PT PT87158499T patent/PT2132206E/pt unknown
- 2008-02-19 HU HUE08715849A patent/HUE026441T2/en unknown
- 2008-02-19 CN CN2008800063770A patent/CN101641352B/zh active Active
- 2008-02-19 MY MYPI20093470 patent/MY150748A/en unknown
- 2008-02-19 MX MX2009008701A patent/MX2009008701A/es active IP Right Grant
- 2008-02-19 ES ES08715849.9T patent/ES2540803T3/es active Active
- 2008-02-19 CL CL200800502A patent/CL2008000502A1/es unknown
- 2008-02-19 UY UY30931A patent/UY30931A1/es active IP Right Grant
- 2008-02-19 UY UY0001038952A patent/UY38952A/es not_active Application Discontinuation
- 2008-02-19 UY UY0001038953A patent/UY38953A/es not_active Application Discontinuation
- 2008-02-19 CA CA2679232A patent/CA2679232C/fr active Active
- 2008-02-19 SI SI200831451T patent/SI2132206T1/sl unknown
- 2008-02-19 PL PL08715849T patent/PL2132206T3/pl unknown
- 2008-02-25 AR ARP080100769A patent/AR065463A1/es active IP Right Grant
- 2008-02-26 JO JOP/2008/0080A patent/JO3018B1/ar active
- 2008-02-26 TW TW097106529A patent/TWI415608B/zh active
- 2008-02-26 TW TW102122083A patent/TWI474821B/zh active
2009
- 2009-07-23 IL IL200060A patent/IL200060A/en active IP Right Grant
- 2009-07-30 TN TNP2009000318A patent/TN2009000318A1/fr unknown
- 2009-08-13 GT GT200900230A patent/GT200900230A/es unknown
- 2009-08-14 HN HN2009001597A patent/HN2009001597A/es unknown
- 2009-08-14 EC EC2009009581A patent/ECSP099581A/es unknown
- 2009-08-14 CU CUP2009000148A patent/CU23874B1/es active IP Right Grant
- 2009-08-14 CR CR10976A patent/CR10976A/es unknown
- 2009-08-14 DO DO2009000205A patent/DOP2009000205A/es unknown
- 2009-08-18 CO CO09085903A patent/CO6220951A2/es not_active Application Discontinuation
- 2009-08-18 ZA ZA200905730A patent/ZA200905730B/xx unknown
- 2009-09-10 MA MA32211A patent/MA31245B1/fr unknown
2013
- 2013-03-13 US US13/801,376 patent/US9051316B2/en active Active
- 2013-08-05 JP JP2013162179A patent/JP5752754B2/ja active Active
2015
- 2015-06-30 CY CY20151100566T patent/CY1116455T1/el unknown
2022
- 2022-05-03 HU HUS2200015C patent/HUS2200015I1/hu unknown
- 2022-05-05 FR FR22C1017C patent/FR22C1017I2/fr active Active
- 2022-05-06 NO NO2022013C patent/NO2022013I1/no unknown
- 2022-05-11 LU LU00260C patent/LUC00260I2/fr unknown
- 2022-06-21 LT LTPA2022512C patent/LTC2132206I2/lt unknown
- 2022-07-08 CY CY2022022C patent/CY2022022I1/el unknown
- 2022-08-11 NL NL301192C patent/NL301192I2/nl unknown

Also Published As

Publication number	Publication date
AU2008221071B2 (en)	2014-01-16
JP2014012678A (ja)	2014-01-23
RU2470932C2 (ru)	2012-12-27
CR10976A (es)	2010-01-13
MX2009008701A (es)	2009-08-27
WO2008104306A2 (fr)	2008-09-04
KR101614164B1 (ko)	2016-04-20
HN2009001597A (es)	2012-01-16
BRPI0808098A2 (pt)	2014-06-17
US20140100243A1 (en)	2014-04-10
EP2132206A2 (fr)	2009-12-16
GT200900230A (es)	2011-11-29
LTC2132206I2 (fr)	2024-12-27
CY2022022I2 (el)	2023-01-05
JO3018B1 (ar)	2016-09-05
CY2022022I1 (el)	2023-01-05
US20100136142A1 (en)	2010-06-03
CU23874B1 (es)	2013-04-19
KR20090129992A (ko)	2009-12-17
DK2132206T3 (en)	2015-07-06
JP5752754B2 (ja)	2015-07-22
BR122020008544B8 (pt)	2021-07-27
PL2132206T3 (pl)	2015-08-31
TWI474821B (zh)	2015-03-01
CO6220951A2 (es)	2010-11-19
RU2009135659A (ru)	2011-04-10
AU2008221071A1 (en)	2008-09-04
CY1116455T1 (el)	2017-03-15
PT2132206E (pt)	2015-08-04
DOP2009000205A (es)	2010-02-28
US8436180B2 (en)	2013-05-07
PE20090724A1 (es)	2009-07-17
TW201340968A (zh)	2013-10-16
SA08290071B1 (ar)	2012-11-03
UY30931A1 (es)	2008-09-30
HUS2200015I1 (hu)	2022-06-28
WO2008104306A3 (fr)	2009-03-19
MY150748A (en)	2014-02-28
NO2022013I1 (en)	2022-05-06
BR122020008544B1 (pt)	2021-02-17
CA2679232C (fr)	2016-07-05
BRPI0808098B1 (pt)	2020-08-04
SI2132206T1 (sl)	2015-08-31
MA31245B1 (fr)	2010-03-01
HK1140194A1 (en)	2010-10-08
EP2132206B1 (fr)	2015-04-01
NZ579230A (en)	2012-04-27
ES2540803T3 (es)	2015-07-13
HRP20150702T1 (hr)	2015-08-14
FR22C1017I2 (fr)	2023-02-03
MY176873A (en)	2020-08-25
US9051316B2 (en)	2015-06-09
NL301192I2 (nl)	2022-12-07
ECSP099581A (es)	2009-09-29
IL200060A (en)	2016-07-31
AR065463A1 (es)	2009-06-10
FR22C1017I1 (fr)	2022-06-17
UY38953A (es)	2021-08-31
LUC00260I2 (fr)	2025-04-25
TWI415608B (zh)	2013-11-21
CA2679232A1 (fr)	2008-09-04
BRPI0808098B8 (pt)	2021-05-25
HUE026441T2 (en)	2016-06-28
IL200060A0 (en)	2010-04-15
TW200843755A (en)	2008-11-16
JP2010519232A (ja)	2010-06-03
CN101641352A (zh)	2010-02-03
CU20090148A7 (es)	2011-04-26
PA8770101A1 (es)	2009-05-15
UA102065C2 (en)	2013-06-10
ZA200905730B (en)	2010-10-27
JP5367586B2 (ja)	2013-12-11
DE102007009494A1 (de)	2008-08-28
UY38952A (es)	2021-08-31
LTPA2022512I1 (fr)	2022-07-11
CN101641352B (zh)	2013-11-20
CL2008000502A1 (es)	2008-06-13

Publication	Publication Date	Title
TN2009000318A1 (en)	2010-12-31	Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
TN2011000466A1 (en)	2013-03-27	Substituted 2-acetamido -5-aryl-1, 2, 4- triazolones and use thereof
JO3199B1 (ar)	2018-03-08	مركبات 5- فلورو-1h- بيرازولوبيريدينات مستبدلة واستخدامها
WO2009068214A3 (fr)	2009-08-20	Pipéridines à substitution hétéroaryl
WO2008155069A3 (fr)	2009-03-19	Oxazolidinones substituées et leur utilisation
PH12012501699A1 (en)	2022-10-05	Bisaryl-bonded aryltriazolones and use thereof
JO2756B1 (en)	2014-03-15	The second preparation of aqueous pyrimidnon containing 4- (4-ciano-2-2 thiourail) and its use)
PH12013500055A1 (en)	2017-08-23	Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
ATE523510T1 (de)	2011-09-15	Substituierte 4-aryl-1,4-dihydro-1,6- naphthyridine und ihre verwendung
WO2008113469A8 (fr)	2009-09-24	Imidazopyrimidines et triazolopyrimidines substituées
WO2008046581A3 (fr)	2008-06-12	Composés tétrahydropyrrolopyrazine substitués et leur utilisation dans des médicaments
IL216967A0 (en)	2012-02-29	17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases
UA102238C2 (en)	2013-06-25	4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof
MX2011012505A (es)	2011-12-14	Piperidinas sustituidas.
TN2009000503A1 (en)	2011-03-31	Substituted (oxazolidinon-5-yl-methyl) -2-thiophene-carboxamides and use thereof in the field of blood coagulation
DE502007006625D1 (de)	2011-04-14	3-cyano-5-thiazaheteroaryl-dihydropyridine und ihrnkungen
MX2010002506A (es)	2010-03-26	Compuestos de nicotinamida sustituidos y uso de estos en medicamentos.
MX2011012507A (es)	2011-12-14	Piperidinas sustituidas.
IL194353A0 (en)	2011-08-01	Lysobactin amides
MX2013002261A (es)	2013-05-22	N-fenetiltriazolonacetamidas sustituidas y su uso.
TW200745132A (en)	2007-12-16	Novel, acyclically substituted furopyrimidine derivatives and use thereof
MX2009013709A (es)	2010-02-01	(oxazolidinon-5-ilmetil)-2-tiofenocarboxamidas sustituidas y su uso en el campo de la coagulación sanguínea.
ATE410443T1 (de)	2008-10-15	Heterocyclyl-substituierte nonadepsipeptide
TN2010000597A1 (en)	2012-05-24	Substituted 7-sulfanylmethyl, 7-sulfinylmethyl and 7-sulfonylmethyl indoles and use thereof